Nrf2 is a key anti-ferroptosis transcription factor in liver cancer, and it can inhibit ferroptosis induced by sorafenib and erastin through the p62-keap1-Nrf2 pathway (Sun et al., 2016). The gene discussed is NFE2L2; the disease is liver cancer.